Allogeneic Versus Autologous Derived Cell Sources for Use in Engineered Bone-Ligament-Bone Grafts in Sheep Anterior Cruciate Ligament Repair by Mahalingam, Vasudevan D. et al.
Allogeneic Versus Autologous Derived Cell Sources
for Use in Engineered Bone-Ligament-Bone Grafts
in Sheep Anterior Cruciate Ligament Repair
Vasudevan D. Mahalingam, MS,1 Nilofar Behbahani-Nejad, MS,1 Storm V. Horine,1 Tyler J. Olsen, BS,2
Michael J. Smietana, PhD,3 Edward M. Wojtys, MD,4 Deneen M. Wellik, PhD,5,6
Ellen M. Arruda, PhD,2,3,7 and Lisa M. Larkin, PhD1,3
The use of autografts versus allografts for anterior cruciate ligament (ACL) reconstruction is controversial. The
current popular options for ACL reconstruction are patellar tendon or hamstring autografts, yet advances in
allograft technologies have made allogeneic grafts a favorable option for repair tissue. Despite this, the mis-
matched biomechanical properties and risk of osteoarthritis resulting from the current graft technologies have
prompted the investigation of new tissue sources for ACL reconstruction. Previous work by our lab has
demonstrated that tissue-engineered bone-ligament-bone (BLB) constructs generated from an allogeneic cell
source develop structural and functional properties similar to those of native ACL and vascular and neural
structures that exceed those of autologous patellar tendon grafts. In this study, we investigated the effectiveness
of our tissue-engineered ligament constructs fabricated from autologous versus allogeneic cell sources. Our
preliminary results demonstrate that 6 months postimplantation, our tissue-engineered auto- and allogeneic
BLB grafts show similar histological and mechanical outcomes indicating that the autologous grafts are a viable
option for ACL reconstruction. These data indicate that our tissue-engineered autologous ligament graft could
be used in clinical situations where immune rejection and disease transmission may preclude allograft use.
Introduction
The anterior cruciate ligament (ACL) is the mostcommonly torn ligament in the knee with an estimated
350,000 ACL-related injuries occurring in the United States
annually.1 Healing of the torn ACL is limited and often re-
quires surgical intervention to restore knee stability and lessen
degenerative features often found in the ACL-deficient knee.2
The current graft options used for ACL reconstructions are
most commonly bone-patellar tendon-bone autografts (PTG)
although the use of hamstring tendon autografts is increasing.3
Donor site morbidity, a major concern with tendon autografts,
however, can lead to postoperative chronic pain and poor
muscle function.4 Although allografts eliminate the issues
related to donor site morbidity, they have other challenges
including graft availability and the increased risks of disease
transmission and immune rejection.2,5 Graft choice should
therefore be dictated by patient-specific characteristics.
There are also overarching concerns shared with the use
of both tendon autografts and allografts. Mismatched bio-
mechanical properties of the tendon graft tissue to replace
the native ligament tissue can cause nonphysiological
loading in the knee.6 These limitations may be associated
with poorer outcomes from ACL reconstructions with re-
ports of failure and recurrent instability in 10–15% of
cases.7–10 Tissue engineering strategies are being studied to
address the limitations associated with current tendon graft
technologies. Most current tissue engineering techniques
being investigated involve the use of natural or synthetic
polymer scaffolds to provide an integrating and degradable
structure for cellular attachment. Although they provide
initial support, no scaffold technology has been developed
that is capable of withstanding the multidirectional me-
chanical forces that native ACLs undergo in vivo. Prolonged
mechanical support during graft healing can lead to issues
with stress-shielding.11,12
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In our laboratory, we have developed a novel method
of tissue engineering three-dimensional multiphasic bone-
ligament-bone (BLB) constructs from bone marrow stromal
cells (BMSCs) capable of generating their own ECM
without the use of scaffolds.13,14 In large animal models, we
have shown that after 6 months in vivo, these engineered
BLB constructs undergo ligamentization developing similar
mechanical properties to those of native ACLs and induce
vascular and neural development exceeding those of PTGs.
These properties make our tissue-engineered BLB con-
structs an attractive alternative to traditional tendon grafts.
Previous work in our laboratory involved the use of al-
logeneic cell sources in our BLB grafts. Our previous
method for BMSC harvest utilized euthanasia and extraction
of bone marrow from the mid-substance of both femurs,
rendering the host animal unavailable for tissue grafting. To
allow for autologous cell sources, we developed a procedure
to fabricate our BLB grafts from BMSCs isolated from bone
marrow aspirations of the ACL compromised patient. Thus,
the first part of this study was to validate the use of the BLB
fabricated from autologous cells in a long-term ACL regen-
eration study. Second, we compared the efficacy of the BLB
grafts from our well-described allogeneic cell source to an
autologous derived cell source. We hypothesized that the
structural and functional outcomes after 6 months of im-
plantation would be similar in both autologous and allo-
geneic models. Autologous grafts would potentially allow
various manufacturing approaches and patient-specific op-
tions with our technology. Our autologous derived BLB graft
could be used if the patient wished to wait for the fabrication
of the BLB graft from their own BMSCs. Conversely, pa-
tients who required expedited surgical intervention could
benefit from possible ‘‘off-the-shelf’’ allogeneic BLB grafts.
Materials and Methods
Experimental design and animal care
We used our previously established model13 of ACL re-
placement in adult Black Suffolk sheep for their anatomical
and functional similarities to the human knee. In this study,
BMSCs were harvested from marrow aspirations from five
adult sheep to fabricate our tissue-engineered constructs for
use as ACL replacement graft tissue. Two constructs were
produced from each aspiration with one implanted into the
aspirated sheep (autologous) and the other implanted into
another sheep (allogenic) as shown in Figure 1 for a total of
10 sheep. Animals were acclimated to the Unit for Labora-
tory Animal Medicine husbandry facilities at the University
of Michigan for at least 1 week before any procedure. Sheep
were given access to food and water ad libitum. All animal
care and animal surgeries were performed in accordance
with the Guide of Care and Use of Laboratory Animals
(Public Health Service, 1996, NIH Publication No. 85–23);
the experimental protocol was approved by the University
Committee for the Use and Care of Animals.
Preparation of cell culture supplies
Unless otherwise indicated, all solutions and media were
prepared and stored at 4C before the isolation and culture
of primary cells and were warmed to 37C in a heated bead
bath before use. The media used in this experiment have
been previously described.13 Briefly, growth medium (GM)
consisted of 78% Dulbecco’s modified Eagle medium
(DMEM; Gibco, Grand Island, NY), with 20% fetal bo-
vine serum (Gibco), 2% antibiotic antimycotic (ABAM;
Gibco), 6 ng/mL basic fibroblast growth factor (Peprotech),
FIG. 1. Experimental design of
study. Bone marrow stromal cells
isolated from a bone marrow aspi-
ration were obtained from five do-
nor sheep and were cultured
in vitro using a previously de-
scribed protocol13,15 to fabricate a
total of 10 BLB constructs. One
construct from each set was then
implanted into the donor (auto) and
another construct was implanted
into a different animal (allo) for use
as ACL replacement grafts for a
total of five sets. ACL, anterior
cruciate ligament; BLB, bone-
ligament-bone.
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0.13mg/mL ascorbic acid-2-phosphotase (Sigma-Aldrich,
St. Louis, MO), and 0.05mg/mL L-proline (Sigma-Aldrich);
differentiation medium (DM) consisted of 91% DMEM, 7%
horse serum albumin (Gibco), 2% ABAM, 0.13mg/mL asc-
2-phos, 0.05mg/mL L-proline, and 2 ng/mL transforming
growth factor beta (Peprotech). About 10- 8 M dexametha-
sone (Sigma-Aldrich) was added to GM and DM for the
culture of bone cells.7
Construct dishes were prepared as described previously13
to form and maintain three-dimensional constructs. Briefly,
100mm diameter cell culture plates were coated with 12mL
Sylgard (type 184 silicon elastomer; Dow Chemical Corp.,
Midland, MI) and allowed to cure for 3 weeks at room
temperature. Before use, plates were decontaminated with
UV light (wavelength 253.7 nm) for 60min and rinsed with
70% EtOH and DPBS.
Isolation and expansion of BMSCs
Marrow aspirations were used to obtain BMSCs for con-
struct fabrication. Bone marrow was aspirated from the iliac
crest of a sheep using a Monoject Illinois needle (Sherwood
Medical Company, St. Louis, MO) with the animal under
general anesthesia induced by intravenous propofol and sus-
tained with inhalation of isoflurane in oxygen. Marrow was
collected using heparinized needles and dispensed into EDTA
blood collection tubes (BD, San Jose, CA) for processing.
The collected marrow aspirate was filtered through a
100mm filter to remove solid debris with 15mL marrow
consolidated into a conical tube with an equivalent volume
of DPBS added. A layer of 15mL Ficoll-Paque Premium
(MNC; GE Healthcare, Munich, Germany) was added on
top of the aspirate solution and was centrifuged (AccuSpin
FR; Beckman Coulter, Inc., Fullerton, CA) at room tem-
perature at 600 g for 30min. The upper layer of plasma was
discarded and the mesenchymal cells contained in the
mononuclear cell layer were transferred into a new conical.
The isolate was then centrifuged at 500 g for 10min and the
supernatant removed. An equivalent volume to the pellet of
ACK lysing buffer (Gibco) was added and mixed for 30 s to
lyse any remaining red blood cells. The conical was then
filled with DPBS and centrifuged at 400 g for 5min to wash
the cells. After the supernatant was removed, the pellet was
resuspended in 20mL GM and a cell count was taken. Cells
were then plated at 40,000–60,000 cells/cm2 in cell culture
dishes.
Fabrication of BLBs
Using previously described methods, the BMSCs were
expanded into ligament and bone lineages.13–15 Briefly,
passage-3 cells in the ligament pathway and passage-4 cells
in the bone pathway were seeded at a density of 21,000
cells/cm2 and switched to DM after 8 days plating. After 2
days in DM, the bone monolayers were rolled with sterile
tweezers into a tube shape and transferred to Sylgard plates.
After 1 to 2 additional days, the bone constructs were then
ready to be incorporated into a ligament monolayer to create
our BLB. Each confluent ligament monolayer was removed
intact from the cell culture plate surface and transferred to
Sylgard plates where they were pinned back into a single
layer. Bone constructs were then pinned on each end of the
ligament monolayer and subsequently surrounded by liga-
ment tissue. The length of the BLB was adjusted with
minutien pins to the desired length of *60mm comprised
of at least a 30mm ligament portion and two 15mm bone
ends. Four of these constructs were placed side-by-side and
allowed to fuse. The DM was changed every 2–3 days. After
2 weeks of formation, two fused sets of four constructs were
combined for an implantation width of *4–5mm at the
ligament region. After an additional 1 week in culture, the
fully formed BLB was ready for implantation. Before im-
planting, the bone ends of the BLB were threaded with
nonabsorbable 5-0 silk suture to allow for passage into the
bone tunnel and fixation onto the periosteum.
Surgical procedure
ACL replacements were performed arthroscopically
based on a previously described procedure.13 Briefly, after
induction of general anesthesia and preparation of the sur-
gical site, two 6mm incisions were made at the joint line on
either side of the patellar tendon for arthroscopic access.
After excising the native ACL, remnants of the stump on
both the femur and tibia were left to aid in anatomical po-
sitioning of the BLB. Drill guides were used to position
Steinmann pins in the center of the tibial and femoral
footprints. Cannulated reamers were used over the pins to
drill 5–6mm bone tunnels. The BLB was then passed
through the bone tunnels with suture and the proximal and
distal ends were secured with suture to the periosteum with
the knee in 30 degrees of flexion. Incisions were closed with
staples and the surgical site was sprayed with Alushield
(Neogen Corp., Lansing, MI).
Explantation
After a 6-month recovery, both knees were explanted for
morphological and mechanical analyses. Following eutha-
nasia, the intra-articular space was exposed by cutting the
patellar tendon and reflecting the patella backward to collect
synovial fluid for analysis. The knee was subsequently
harvested by removing the tibia and femur and taken for
mechanical testing. Anterior drawer testing of the knee at 45
degrees was performed with the knee capsule intact. The
knee was then dissected to the BLB or contralateral/native
ACL (C-ACL) and the medial condyle was removed for
visualization of the entire graft for mechanical testing.
Following testing, the BLB and ACL were dissected from
the bone insertions and harvested for histology.
Histological analysis
For histological preparation, samples were fixed in 10%
neutral buffered formalin for 8 days and stored in 70%
ethanol at 4C until processing. Each tissue was sectioned in
a microtome (Leica RM 2155) at 6 mm, placed onto Su-
perfrost Plus microscopy slides, and placed in 60C oven for
1 h to dry. For morphological characteristics, sections were
stained with hematoxylin and eosin (H&E). Immunohisto-
chemistry (IHC) staining with specific antibodies was per-
formed to detect the presence of elastin and collagen type 1.
Picrosirius red staining was used for analysis of collagen
content and fiber organization. Semi-quantitative analysis
was performed of the collagen fiber birefringence using
previously established methods.16 Under uniform conditions,
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sections stained for picrosirius red were imaged at
10· magnification in a single session under monochromatic
polarized light rotated in the plane for maximum brightness.
Images were imported using ImageJ software into 8 bit gray
scale showing collagenous material representing a gray scale
value 1–255 and noncollagenous components as dark with a
gray scale value of zero. Mean gray scale values of 10 ran-
domly selected rectangular areas (50· 50mm) from repre-
sentative sections of each animal were obtained using
ImageJ to assign a brightness value for comparison.
To deparaffinize the slides with paraffin sections for IHC,
slides were washed three times in xylene for 3min, twice in
100% ethanol for 2min, twice in 95% ethanol for 2min, and
once in 70% ethanol for 2min. Following deparaffinization,
slides were washed in phosphate buffered saline (PBS)-
0.1% Triton X-100 (PBST; Sigma-Aldrich) for 15min at
room temperature. Using a hydrophobic pen, sections were
circled for blocking and antibody staining. Sections were
covered in blocking solution containing PBST with 3%
bovine serum albumin (Sigma-Aldrich) for 30min at room
temperature. Primary antibodies were diluted in blocking
solution and added to the sections and incubated overnight
at 4C in a hydration chamber. The dilutions of the primary
antibodies used were as follows: 1:35 of rabbit anti-elastin
(#AB2039; Millipore, Billerica, MA); and 1:100 of rabbit
anti-collagen type I (#AB292; Abcam, Cambridge, MA).
Slides were then washed for 5min in PBST at room tem-
perature three times for a total of 15min. Secondary anti-
bodies were diluted at 1:500 in blocking solution in the dark
and added to the sections. The slides were kept in a hy-
dration chamber and incubated at room temperature for
2.5 h. The slides were then washed for 15min in PBS at
room temperature three times for a total of 45min. Nuclei
were stained using Prolong Gold with DAPI (Sigma-
Aldrich) to each section. Slides were then coverslipped and
incubated overnight at room temperature before imaging
with an Olympus BX-51 microscope.
Knee laxity testing
Knee laxity was measured using a custom-designed an-
terior drawer tester using an MTS 810 servohydraulic test
system with a 25 kN load cell. The bones were potted in
grips with a polymer and secured with two ¼¢¢-20 screws.
Ink markings were placed at a known distance onto the
femur and tibia grips for displacement tracking. The test
comprised of a 0.5mm/s extension until a 50N force was
achieved. Images were collected with a Grasshopper IEEE-
1394b digital camera (Point Grey, British Columbia, CA)
and analysis for displacement was determined using Meta-
Morph software.
Mechanical testing
After the drawer test, knee tissue was further dissected
away leaving only the BLB or C-ACL attached at both tibial
and femoral insertions. The length of the ligament and the
width and thickness of the proximal, middle, and distal re-
gions were recorded. The cross-sectional areas from these
three locations were averaged and used as the representative
area for stress calculations. The knee was repositioned for a
flexion angle of 30 degrees by fixing the tibia and femur
grips at 90 and 60 degrees respectively in the sagittal plane.
Graphite powder was blown onto the specimen to create a
surface pattern for optical displacement measurement using
digital image correlation (DIC) to compute full-field strain
contours. Uniaxial tension tests at a strain rate of 0.05/s for a
loading time of 7.5 s were then conducted on the BLB and
ACL specimens to obtain the stiffness using previously
developed testing protocols.13 A Photron high-speed camera
was used for synchronized force and image acquisition with
a custom-developed LabView program. The load-unload
cycle for each specimen was run in triplicate. VIC-2D
Software (Correlated Solutions, Columbia, SC) was used for
DIC analysis.
Statistical analysis
Comparisons among the three groups were done using
one-way analysis of variance (ANOVA) with Tukey’s
post-hoc test. A p-value < 0.05 for all statistical tests was
considered significant. All data were reported as mean –
standard deviation.
Results
The BLB constructs fabricated from bone marrow aspirates
using our prior methodology were all produced and implanted
successfully demonstrating similar morphology and robust-
ness to the constructs fabricated from whole femoral bone
marrow extractions used in our previous study.12 Two sheep
from the allogeneic BLB group were excluded from the
study. One of the sheep developed an illness unrelated to the
experiment and was unable to recover. The explanted liga-
ment from a different sheep was compromised by an equip-
ment error during uniaxial tensile testing precluding
determination of tangent modulus but was able to be saved
for histology.
Size of explanted BLB compared to C-ACL
After 6 months in vivo, explanted autologous BLBs
achieved an average length of 18.7– 2.7mm with allogeneic
BLBs reaching 18.5– 1.2mm (Fig. 2A). The average CSAs of
autologous BLBs were 27.7– 5.0 cm2 and allogeneic BLB
CSAswere 29.7– 10.5mm2 (Fig. 2B). The average length and
CSA of the C-ACLs were 21.4– 3.1mm and 39.1– 9.2mm2
respectively. One-way ANOVA showed no statistically sig-
nificant difference ( p> 0.05) between the average lengths
F(5,51)= 1.7, and CSAs F(5,54)= 2.3 of the groups.
Analysis of structure, vascularization, innervation, and
elastin of the BLB
Histological observations showed similarities between
both autologous and allogeneic derived BLBs. H&E sec-
tions demonstrated advanced remodeling and tissue regen-
eration exhibited by a native collagen crimp pattern with
fibers aligned along vertical axis of the tissue (Fig. 3).
Compared to the C-ACL, both autologous and allogeneic
graft types similarly showed an advance in phenotype after
implantation and demonstrated signs of regeneration sug-
gested by the prominent vasculature, innervation, and in-
creased cellular density seen on H&E, collagen type I, and
elastin staining (Figs. 3 and 5). Semi-quantitative analysis of
collagen birefringence was performed to compare collagen
alignment and maturation (Fig. 4). Explanted allograft and
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autologous BLBs had very similar mean gray scale values
(allo: 90– 11, auto: 90– 9) and were lower than C-ACL
knees (115– 16), with the difference being statistically sig-
nificant ( p< 0.05), F(2,13)= 7.
Knee laxity
The knee laxity for the autologous implanted knees av-
eraged 1.8– 1.2mm (n= 5) while that of the allograft knees
was 1.9– 0.4mm (n= 4). The C-ACL knee laxity averaged
0.5– 0.3mm (n= 15) (Fig. 6A). One-way ANOVA showed
no significant difference between autologous and allograft
knee laxity ( p> 0.05), but both groups had significantly in-
creased laxity ( p< 0.001) compared to the C-ACL knees,
F(3,26)= 7.9. When comparing allogeneic and autologous
knees within BLB cohorts there did not appear to be an
appreciable trend (Fig. 6B). Set #5 was excluded from this
analysis due to the unfit allogeneic animal in this group
described earlier.
Modulus analysis of BLB
The tangent modulus (the slope of the stress–strain curve
at a specified strain range) for the autologous group aver-
aged 46 – 15MPa (n = 5), whereas the tangent modulus of
the allograft BLBs averaged 35 – 13MPa (n = 3) at a strain
range of 0.035–0.080 (Fig. 7A). The tangent modulus data
indicated no significant differences between the two graft
types ( p > 0.05). Both grafts achieved *23–30% of the
average C-ACL modulus, which was 158– 32MPa (n = 12)
at a strain range of 0.040–0.10. Comparison of the allo-
geneic and autologous explanted BLBs when matched
within BLB cohorts did not show a consistent trend (Fig.
7B). Sets #3 and #5 were excluded from the analysis due
to the loss of the two allogeneic test subjects mentioned
previously.
FIG. 3. Longitudinal sec-
tions of C-ACL and ex-
planted BLB (Allo/Auto)
after 6 months in vivo. H&E
staining (A–C) was used to
ascertain general structure
and morphology. Im-
munohistochemical staining
for Elastin (D–F) and Type I
Collagen (G–I) indicated
positive staining in both Allo
(E, H) and Auto (F, I) with
organization and staining
showing similarities to
C-ACL (D, G). All images
taken at 40· magnification
with scale bars indicating
100 mm. H&E, hematoxylin
and eosin. Color images
available online at www
.liebertpub.com/tea
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FIG. 2. Comparisons of length (A) and cross-sectional
area (B) of C-ACL, explanted Allo BLB, and Auto BLB
after 6 months in vivo. Values are mean – standard devia-
tion. There were no significant differences found in the
length and cross-sectional area of the C-ACL, Allo BLB,
and Auto BLB. C-ACL, contralateral/native ACL.
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Discussion
The decision to use patient-derived tendon autografts
versus cadaveric tendon allografts for current ACL re-
construction procedures is multifactorial. Autograft use has
demonstrated earlier graft incorporation17 but warrants con-
cern of donor site morbidity at the site of harvest, whereas
allogeneic tissues can present with immune rejection and
disease transmission but requires less time in surgery. Both
of these tendon grafts, however, are poor biomechanical
matches for native ACL tissue.
Our scaffoldless tissue engineering approach to develop
allogeneic ACL grafts has been shown to be effective in
restoring function, even surpassing outcomes seen with
current tendon graft options in our allogeneic models.12 For
this study, we developed a BMSC isolation protocol using
bone marrow aspirates for autologous construct implanta-
tion adapted from our previously established nonrecovery
allogeneic isolation method of utilizing the whole marrow
contents of a femur. From this new bone marrow aspiration
technique, we were able to produce BLB constructs in vitro
that were structurally and functionally similar to those made
via our allogeneic model. Furthermore, by fabricating BLBs
for each set of autologous and allogeneic animals from the
same initial aspirate, we were able to eliminate batch to
batch variation between donation methods. Postimplantation,
as was seen with our previous studies,13 these constructs also
did not appear to elicit an immune rejection response in our
animals. After 6 months in vivo, both autologous and allo-
geneic BLBs showed similar mechanical outcomes. Histo-
logical evaluation of both BLB graft types indicated an
analogous regeneration containing vasculature, innervation,
and increased cellular density. These results demonstrate that
using autologous cells for fabrication of BLBs is a viable
option with our methods for ACL reconstruction.
FIG. 5. Cross sections of C-ACL and explanted BLB
(Allo/Auto) after 6 months in vivo. H&E images (A–C) at
40· showed pronounced vasculature confirmed by CD31
(D–F) antibody staining in both Allo (B, E) and Auto BLBs
(C, F) indicating tissue regeneration. All images taken at
40· magnification with scale bars indicating 100 mm. Color
images available online at www.liebertpub.com/tea
FIG. 4. Collagen Organi-
zation of C-ACL and ex-
planted BLB (Allo/Auto)
after 6 months in vivo. Pi-
crosirius Red staining was
used for semiquantitative
analysis of collagen bi-
refrigence. Representative
sections of C-ACL (A), Allo
(B), and Auto (C) tissues
shown at 10· magnification
with scale bars indicating
500 mm. Asterisks (*) denote
significance from C-ACL.
Error bars indicate standard
deviation. Color images
available online at www
.liebertpub.com/tea
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The use of allogeneic cells and tissues has been com-
prehensively investigated both in research and clinical set-
tings.18 The safety and efficacy of these treatments continue
to advance by taking additional precautions of donor se-
lection and sterile processing and preservation of the tis-
sues.19 However, patient and physician perceptions of
allogeneic sources can be negative due to risks of disease
transmission and immune rejection. In some patients, there
are concerns associated with the use of cells and tissues
other than their own. Even for ubiquitous and routine pro-
cedures such as blood transfusion, which has extensive do-
nor screening and laboratory testing to minimize risk of
disease transmission, many patients20 and even countries21
are opting for autologous blood donations. In the field of
tissue engineering, although BMSCs have been shown to be
immunomodulatory and utilized in tissue transplantation for
their immunosuppressive effects to combat graft-versus-host
disease,22 the notion of implanting constructs derived from
allogeneic sources may still carry negative connotations for
the patient. In this study, we have shown that autologous
derived BLBs have very similar outcomes to allogeneic
BLBs. In theory, patients seeking peace of mind by using
autologous derived constructs would be able to do so after
only needing to undergo a simple bone marrow aspiration
preoperative procedure.
By incorporating our technology within the autologous
versus allogeneic cell source paradigm, we have determined
that our constructs have increased versatility in that they
have the potential to be used in either application. Further
work is needed to fully characterize our autologous and
allogeneic BLBs in vivo to determine the fate of the im-
planted cellular and extracellular components. Additionally,
while the findings of this study suggest that outcomes from
autologous derived grafts are not superior to those of allo-
geneic grafts, continued investigation is required to de-
velop our technology by finding interventions in vitro during
construct fabrication or in vivo during construct remodeling
to enhance biomechanical outcomes to further restore native
knee function.
A limitation of this work that is shared with fresh tissue-
engineered grafts is the length of time required for graft
fabrication and the subsequent viable time of the graft after
formation. With our methods, total in vitro time required is
*5–6 weeks from aspiration to implantable graft. Ad-
ditionally, due to the cost and resource demands of this
project, it was necessary to have mechanical and histologi-
cal assessments performed on the same tissue. Mechanical
tests were performed first at a conservative level to prevent
damage to the tissue. As a result, there is a higher variation
in the selection of the strain region from the linear portion of
the stress–strain curve to calculate tangent modulus. It
should also be noted that due to these constraints and the
loss of two animals in the allogeneic group, there were a
limited number of test subjects and that these data therefore
represent preliminary findings.
Our BLB technology has been shown to exceed morpho-
logical and biomechanical outcomes of patellar tendon grafts
by actually regenerating ligament tissue and recovering
FIG. 7. Tangent modulus
of C-ACL and explanted
BLB (allo/auto) grafts. No
significant differences were
found between allo and auto
BLBs (A). No discernible
trend between matched sets
of Allo BLB versus Auto
BLB was found (B). Values
are mean – standard devia-
tion. Asterisks (*) denote
significance from C-ACL.
FIG. 6. Knee laxity of C-ACL and explanted BLB (Allo/Auto) after 6 months in vivo. No significant differences were
found between the Allo and Auto BLB knee laxities, however, they were both significantly more lax than the C-ACL (A).
Comparison of Allo BLB versus Auto BLB between sets did not appear to show a consistent trend (B). Thick bars show the
mean and error bars indicate standard deviation. Asterisks (*) denote significance from C-ACL.
ENGINEERED LIGAMENT FOR ACL REPAIR 1053
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
native biomechanics to the knee.13 In this study, we were able
to expand on our fabrication technology to the harvesting of
BMSCs from bone marrow aspirations for performing au-
tologous donations. We have shown that both autologous and
allogeneic grafts result in similar biomechanical and histo-
logical outcomes after 6 months implantation. Both graft
types grew to the size of the C-ACL in vivo and when
compared to each other, had similar biomechanical and his-
tological outcomes. Each graft exhibited a ligamentous crimp
pattern with collagen alignment, demonstration of remodeling
through vascularization, and comparable knee laxities and
mechanical moduli. These results demonstrate that our tissue-
engineered BLB graft could be manufactured from autolo-
gous or allogeneic cell sources for use in clinical situations
where immune rejection and disease transmission are con-
cerns for the patient, thereby expanding the versatility of our
technology.
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